AB Science S.A.

AB Science is a French pharmaceutical company founded in 2001 and headquartered in Paris, France. The company specializes in the research, discovery, development, and commercialization of innovative drugs, primarily protein kinase inhibitors (PKIs), targeting diseases with high unmet medical needs in both human and veterinary medicine.

AB Science's pipeline is centered around two main compounds: masitinib, a selective tyrosine kinase inhibitor, and AB8939, a new generation microtubule destabilizer. Masitinib is being developed across various therapeutic areas, including oncology, inflammatory diseases, and neurological degenerative disorders such as Amyotrophic Lateral Sclerosis (ALS), progressive forms of multiple sclerosis, Alzheimer's Disease, indolent severe systemic mastocytosis, severe asthma, and sickle cell disease. The company also markets Masivet®, a masitinib-based product registered for veterinary use in canine mast cell tumors.

Recent developments for AB Science include securing a clinical trial funding insurance for its Phase III ALS trial and recent capital increases. The company has also announced the identification of a plasma biomarker for masitinib in ALS and received patent allowances for masitinib in prostate cancer and multiple sclerosis. Alain Moussy serves as the Co-founder, Chairman, and Chief Executive Officer. The company is currently reviewing its strategic priorities, including deprioritizing certain mastocytosis and mast cell activation programs, following discussions with European health authorities regarding resources for clinical studies.